Contrasting Nyxoah (NASDAQ:NYXH) and HeartBeam (NASDAQ:BEAT)

Nyxoah (NASDAQ:NYXH) and HeartBeam (NASDAQ:BEAT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Volatility and Risk

Nyxoah has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, HeartBeam has a beta of -0.86, meaning that its stock price is 186% less volatile than the S&P 500.

Earnings & Valuation

This table compares Nyxoah and HeartBeam”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33 million	5.78	-$101.92 million	($2.48)	-0.68
HeartBeam	N/A	N/A	-$21.01 million	($0.56)	-1.34

HeartBeam has lower revenue, but higher earnings than Nyxoah. HeartBeam is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Nyxoah and HeartBeam’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
HeartBeam	N/A	-1,034.04%	-434.40%

Analyst Ratings

This is a summary of current ratings for Nyxoah and HeartBeam, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1	1	2	0	2.25
HeartBeam	1	2	4	1	2.63

Nyxoah currently has a consensus price target of $7.00, suggesting a potential upside of 314.20%. HeartBeam has a consensus price target of $4.33, suggesting a potential upside of 477.78%. Given HeartBeam’s stronger consensus rating and higher possible upside, analysts plainly believe HeartBeam is more favorable than Nyxoah.

Insider & Institutional Ownership

7.8% of HeartBeam shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

HeartBeam beats Nyxoah on 9 of the 14 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About HeartBeam

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.